Skip to main content
Clinical Trials/ISRCTN30952488
ISRCTN30952488
Completed
Phase 4

A series of randomised controlled N-of 1 trials in patients who have discontinued or are considering discontinuing statin use due to muscle-related symptoms to assess if atorvastatin treatment causes more muscle symptoms than placebo.

ondon School of Hygiene and Tropical Medicine0 sites200 target enrollmentMay 12, 2016

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
ondon School of Hygiene and Tropical Medicine
Enrollment
200
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

2017 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/29197834 protocol 2021 Results article in https://doi.org/10.1136/bmj.n135 results (added 25/02/2021) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33709907/ results (added 15/03/2021) 2019 Results article in https://doi.org/10.3390/healthcare7040134 (added 14/06/2023)

Registry
who.int
Start Date
May 12, 2016
End Date
September 30, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ondon School of Hygiene and Tropical Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. Adults (aged 16 and over)
  • 2\. Prescribed statin treatment in the last 3 years
  • 3\. Stopped OR considering stopping statin treatment due to muscle symptoms
  • 4\. Provided fully informed consent

Exclusion Criteria

  • 1\. Any previously documented serum alanine aminotransferase (ALT) levels at or above three times the upper limit of normal
  • 2\. Have persistent, generalised, unexplained muscle pain (whether associated or not with statin use) and have creatinine kinase (CK) levels greater than 5 times the upper limit of normal
  • 3\. Should not be using atorvastatin 20mg daily in the opinion of the general practitioner

Outcomes

Primary Outcomes

Not specified

Similar Trials